This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
EUEMA:by INNUSDailyMed:SorafenibUSFDA:Sorafenib
AU:D
L01EX02(WHO)
AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
284461-73-0
216239
5711
DB00398
187440
9ZOQ3TZI87
D08524D06272
CHEBI:50924
ChEMBL1336
BAX (PDBe,RCSB PDB)
DTXSID7041128
Interactive image
CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)Key:MLDQJTXFUGDVEO-UHFFFAOYSA-N
Sorafenib, sold under the brand nameNexavar,is akinaseinhibitor drug approved for the treatment of primary kidney cancer (advancedrenal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
